Preferred Label : KRAS Inhibitor BI 3706674; 
NCIt definition : An orally bioavailable small molecule inhibitor that targets the oncogenic KRAS wild-type
               (WT) and various KRAS mutant forms, such as KRAS G12C, with potential antineoplastic
               activity. Upon oral administration, KRAS inhibitor BI 3706674 selectively binds to
               KRAS, thereby inhibiting KRAS-dependent signaling and inhibits growth and survival
               of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of
               oncogenes, serves an important role in cell signaling, division and differentiation.
               Mutations of KRAS may induce constitutive signal transduction leading to tumor cell
               growth, proliferation, invasion, and metastasis.; 
Molecule name : BI-3706674; BI 3706674; 
NCI Metathesaurus CUI : CL1921205; 
         
         
            Origin ID : C202247; 
UMLS CUI : C5907968; 
 Semantic type(s) Semantic type(s)
 concept_is_in_subset concept_is_in_subset
 has_target has_target